E David Crawford

Summary

Publications

  1. ncbi request reprint Screening for prostate cancer: current recommendations
    Shandra S Wilson
    Department of Urologic Oncology, Anschutz Cancer Center, 1665 North Ursula, Aurora, CO 80010, USA
    Urol Clin North Am 31:219-26. 2004
  2. ncbi request reprint Controversies regarding screening for prostate cancer
    E David Crawford
    Department of Urologic Oncology, University of Colorado, Denver, CO 80010, USA
    BJU Int 100:5-7. 2007
  3. doi request reprint Challenges and recommendations for early identification of metastatic disease in prostate cancer
    E David Crawford
    University of Colorado, Denver Aurora, CO Electronic address
    Urology 83:664-9. 2014
  4. ncbi request reprint Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial
    M Scott Lucia
    Department of Pathology, University of Colorado Denver and Health Sciences Center, 4200 E Ninth Ave, Box B 216, Denver, CO 80262, USA
    J Natl Cancer Inst 99:1375-83. 2007
  5. ncbi request reprint The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
    Ali Ziada
    UCHSC, 4200 E 9th Ave C 319, Denver, CO, USA
    Prostate 60:332-7. 2004
  6. doi request reprint Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens
    E David Crawford
    Division of Urology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA
    Prostate 73:778-87. 2013
  7. ncbi request reprint High Gleason scores and lower prostate-specific antigen levels in a single institution over the past decade
    Zinelabidine Abouelfadel
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Clin Prostate Cancer 1:115-7. 2002
  8. ncbi request reprint Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy
    Al Baha Barqawi
    Division of Urology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 62:872-6. 2003
  9. doi request reprint Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone
    E David Crawford
    University of Colorado, Anschutz Medical Campus, Aurora, 80045, USA
    BJU Int 108:1743-9. 2011
  10. ncbi request reprint Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival
    Kyle O Rove
    Section of Urologic Oncology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA
    Oncology (Williston Park) 25:1362-70, 1375-81, 1387. 2011

Detail Information

Publications91

  1. ncbi request reprint Screening for prostate cancer: current recommendations
    Shandra S Wilson
    Department of Urologic Oncology, Anschutz Cancer Center, 1665 North Ursula, Aurora, CO 80010, USA
    Urol Clin North Am 31:219-26. 2004
    ..It is hoped that prospective, randomized, long-term screening studies, such as the PLCO and ERSCP trials, will show improved survival using the admittedly imperfect PSA marker in prostate cancer screening...
  2. ncbi request reprint Controversies regarding screening for prostate cancer
    E David Crawford
    Department of Urologic Oncology, University of Colorado, Denver, CO 80010, USA
    BJU Int 100:5-7. 2007
  3. doi request reprint Challenges and recommendations for early identification of metastatic disease in prostate cancer
    E David Crawford
    University of Colorado, Denver Aurora, CO Electronic address
    Urology 83:664-9. 2014
    ..The aim of this review was to present the recommendations from the group to identify optimal strategies for early identification of metastases in patients with prostate cancer. ..
  4. ncbi request reprint Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial
    M Scott Lucia
    Department of Pathology, University of Colorado Denver and Health Sciences Center, 4200 E Ninth Ave, Box B 216, Denver, CO 80262, USA
    J Natl Cancer Inst 99:1375-83. 2007
    ..We assessed whether the increased high-grade prostate cancer associated with finasteride in the PCPT was due to finasteride's potential effects on tumor morphology or prostate size...
  5. ncbi request reprint The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
    Ali Ziada
    UCHSC, 4200 E 9th Ave C 319, Denver, CO, USA
    Prostate 60:332-7. 2004
    ..To investigate the efficacy and toxicity of the antibody to the HER-2/neu receptor (trastuzumab, Herceptin) in the treatment of advanced hormone-refractory prostate cancer (HRPC)...
  6. doi request reprint Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens
    E David Crawford
    Division of Urology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA
    Prostate 73:778-87. 2013
    ....
  7. ncbi request reprint High Gleason scores and lower prostate-specific antigen levels in a single institution over the past decade
    Zinelabidine Abouelfadel
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Clin Prostate Cancer 1:115-7. 2002
    ..Continued screening for prostate cancer is resulting in the diagnosis of more unfavorable cancers...
  8. ncbi request reprint Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy
    Al Baha Barqawi
    Division of Urology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 62:872-6. 2003
    ..To evaluate the efficacy and tolerability of combined finasteride and low-dose flutamide for prostate-specific antigen (PSA)-only recurrence after definitive therapy and to determine the predictors of recurrence-free survival...
  9. doi request reprint Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone
    E David Crawford
    University of Colorado, Anschutz Medical Campus, Aurora, 80045, USA
    BJU Int 108:1743-9. 2011
    ..This study examines a larger number of men in a diverse US population to determine the prognostic value of a man's baseline or first PSA...
  10. ncbi request reprint Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival
    Kyle O Rove
    Section of Urologic Oncology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA
    Oncology (Williston Park) 25:1362-70, 1375-81, 1387. 2011
    ....
  11. ncbi request reprint Prostate cancer in a man with multiple previous cancers
    Thomas Flaig
    University of Colorado, Health Sciences Center, Aurora, Colorado, USA
    Oncology (Williston Park) 21:611-4. 2007
  12. ncbi request reprint Screening for prostate cancer
    Shandra S Wilson
    Department of Urologic Oncology, Anschutz Cancer Center, Denver, CO, USA
    Clin Prostate Cancer 3:21-5. 2004
    ..These measures include prevention, screening, improved curative treatment, and the transformation of an acute lethal disease to a chronic, tolerable one. This summary focuses on the screening aspects of prostate cancer...
  13. ncbi request reprint Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program
    Al Baha Barqawi
    Section of Urologic Oncology, University of Colorado Health Science Center School of Medicine, Denver, Colorado, USA
    Urology 65:708-12. 2005
    ..To assess the effect of aging and body mass index (BMI) on both serum total prostate-specific antigen (tPSA) and complexed PSA (cPSA) from the results of the 2003 Prostate Cancer Awareness Week national screening database...
  14. pmc Comorbidity and mortality results from a randomized prostate cancer screening trial
    E David Crawford
    University of Colorado Health Sciences Center, Denver, CO, USA
    J Clin Oncol 29:355-61. 2011
    ..However, results analyzed by comorbidity strata remain unknown...
  15. ncbi request reprint Herbal and vitamin supplement use in a prostate cancer screening population
    Albaha Barqawi
    Section of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 63:288-92. 2004
    ....
  16. ncbi request reprint Recent advances in hormonal therapy for advanced prostate cancer
    Siam Oottamasathien
    Department of Surgery, Division of Urology, University of Colorado, Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 17:1047-52; discussion 1054-8. 2003
    ..Although hormonal therapy is an important treatment modality for advanced prostate cancer, long-term treatment carries significant side effects that need to be considered...
  17. ncbi request reprint The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms
    Al Baha Barqawi
    Urologic Oncology Department, School of Medicine, University of Colorado Health Science Center, Denver, Colorado, USA
    BJU Int 100:853-7. 2007
    ..To assess the effect of tamsulosin on the Sexual Health Inventory for Men (SHIM) score in men diagnosed with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)...
  18. doi request reprint Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer
    Kyle O Rove
    University of Colorado, Anschutz Medical Campus, Division of Urology, Aurora, CO 80045, USA
    Curr Opin Urol 23:208-13. 2013
    ..New US Food and Drugs Administration approved pharmaceutical agents further eliminate testosterone ligand or its activity via inhibition of key synthetic enzymes and through strong inhibition of the androgen receptor...
  19. ncbi request reprint Use of algorithms as determinants for individual patient decision making: national comprehensive cancer network versus artificial neural networks
    E David Crawford
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center and the University of Colorado Cancer Center, Denver, Colorado 80262, USA
    Urology 62:13-9. 2003
    ....
  20. ncbi request reprint Intermediate- to high-risk prostate cancer patient treated with radiation therapy
    E David Crawford
    University of Colorado Health Sciences Center, Denver, USA
    Oncology (Williston Park) 18:1105-10. 2004
  21. ncbi request reprint Preventing and treating the complications of hormone therapy
    Ravi J Kumar
    Urologic Oncology, University of Colorado Health Sciences Center, 4200 East 9th Avenue C 319, Denver, CO 80262, USA
    Curr Urol Rep 6:217-23. 2005
    ....
  22. ncbi request reprint Targeted focal therapy: a minimally invasive ablation technique for early prostate cancer
    E David Crawford
    University of Colorado, Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 21:27-32; discussion 33-4, 39. 2007
    ..In this review, we present the current status of our knowledge about this procedure and the most important challenges that need to be addressed. We also present the initial results with this approach at our center...
  23. ncbi request reprint Artificial neural networks for predictive modeling in prostate cancer
    Eduard J Gamito
    University of Colorado Health Sciences Center, C 314, 200 East 9th Avenue, Denver, CO 80262, USA
    Curr Oncol Rep 6:216-21. 2004
    ..This article provides an overview of the theoretical basis of ANNs, how they function, their strengths and limitations, and examples of how ANNs have been used to develop predictive models for the management of prostate cancer...
  24. ncbi request reprint PSA testing: what is the use?
    E David Crawford
    University of Colorado, Denver, CO 80262, USA
    Lancet 365:1447-9. 2005
  25. ncbi request reprint Prostate cancer chemoprevention: an overview of United States trials
    Albaha Barqawi
    Division of Urologic Oncolgy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Urol 171:S5-8; discussion S9. 2004
    ..We review the current status of clinical trials investigating the use of interventions designed to reduce the risk of prostate cancer...
  26. ncbi request reprint Surgical management of prostate cancer: optimizing patient selections and clinical outcome
    Paul D Maroni
    Division of Urology, Department of Surgery, University of Colorado Health Sciences Center, Denver, 80252, USA
    Surg Oncol Clin N Am 14:301-19. 2005
  27. ncbi request reprint Controversies of androgen ablation therapy for metastatic prostate cancer
    Shandra S Wilson
    Department of Urologic Oncology, 1665 North Ursula, Aurora, CO 80010, USA
    Curr Pharm Des 12:799-805. 2006
    ....
  28. ncbi request reprint The role of alpha-blockers in the management of lower urinary tract symptoms in prostate cancer patients treated with radiation therapy
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Aurora, CO 80010, USA
    Am J Clin Oncol 29:517-23. 2006
    ..This review will analyze the current state of knowledge of LUTS secondary to RT for prostate cancer and review treatment options for this complication...
  29. doi request reprint Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts
    Kyle O Rove
    Division of Urology, University of Colorado, Anschutz Medical Campus, Mail Stop F710, P O Box 6510, Aurora, CO 80045, USA
    World J Urol 30:137-42. 2012
    ..This report aims to clarify the issues specific to the PSA test, prostate cancer, sources of bias, and the future of screening...
  30. ncbi request reprint The current use and future trends of focal surgical therapy in the management of localized prostate cancer
    Al B Barqawi
    Urologic Oncology Department, School of Medicine, University of Colorado Health Science Center, Denver, CO, USA
    Cancer J 13:313-7. 2007
    ..In addition, we will discuss future promising tools in MIT such as photodynamic therapy and the target focal therapy approach as a new trend for the treatment of organ-confined low-volume disease...
  31. doi request reprint The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions
    Natalie J Serkova
    Department of Anesthesiology and Radiology, Biomedical MRI MRS, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Prostate 68:620-8. 2008
    ..In this study, proton nuclear magnetic resonance spectroscopy ((1)H-NMRS) is used to assess potential metabolic markers of prostate cancer (PCa) in human expressed prostatic secretions (EPS)...
  32. doi request reprint Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases
    E David Crawford
    University of Colorado, Anschutz Medical Campus, Aurora, Colorado 80045, USA
    J Urol 188:1726-31. 2012
    ..We investigated the value of the PCA3 (prostate cancer gene 3) urine test in predicting the likelihood of diagnosis of cancer before biopsy...
  33. ncbi request reprint Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma
    Thomas D Denberg
    University of Colorado at Denver and Health Sciences Center, Denver, CO, USA
    BJU Int 98:335-40. 2006
    ....
  34. doi request reprint Understanding the epidemiology, natural history, and key pathways involved in prostate cancer
    E David Crawford
    Section of Urologic Oncology, University of Colorado Health Science Center, Denver, Colorado, USA
    Urology 73:S4-10. 2009
    ..A substantial research effort has recently focused on understanding the pathways involved in the disease's emergence and progression, particularly the 5alpha-reductase pathway...
  35. ncbi request reprint Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, Washington, DC, USA
    J Urol 175:1286-90; discussion 1290. 2006
    ..A large fraction of screened men have low (less than 2 ng/ml) initial PSA. The yield over time of positive PSA screens (ie more than 4 ng/ml) in these men has not been well characterized in large cohorts in the United States...
  36. doi request reprint PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Eur Urol 54:262-73. 2008
    ..Despite the substantive societal impact of prostate cancer, the medical community is currently divided on the balance between benefit and harm of screening for prostate cancer using prostate-specific antigen (PSA)...
  37. ncbi request reprint Biomorphometric analysis of human prostatic carcinoma by using three-dimensional computer models
    Priya N Werahera
    Department of Pathology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Hum Pathol 35:798-807. 2004
    ..Moreover, our 3-dimensional computer modeling system improves upon other systems: It is more than a simple extension of the planimetric technique, and it is able to demarcate clearly the boundaries of Gleason grades just 1 grade apart...
  38. ncbi request reprint Epidemiology of prostate cancer
    E David Crawford
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center and the University of Colorado Cancer Center, Denver, Colorado 80262, USA
    Urology 62:3-12. 2003
    ..In contrast, mortality rates for men diagnosed with localized or regional disease increased gradually during most of the 1990s before decreasing slightly among white men and reaching plateaus among African Americans...
  39. ncbi request reprint Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma
    L Michael Glode
    Oncology Urology Department, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Cancer 98:1643-8. 2003
    ....
  40. ncbi request reprint Focal therapy in prostate cancer: future trends
    Al Barqawi
    University of Colorado Health Sciences Center, 4200 E 9th Ave, C 319, Denver, Colorado 80262, USA
    BJU Int 95:273-4. 2005
  41. ncbi request reprint A 42-year-old woman with breast cancer
    E David Crawford
    University of Colorado Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 17:614; discussion 615-20. 2003
    ..At this point, we recommend tamoxifen, with consideration to adding goserelin (Zoladex) if the patient does not remain amenorrheic. The patient chose to enter the Intergroup trastuzumab trial...
  42. ncbi request reprint The management of high risk prostate cancer
    Bulent Akduman
    Section of Urologic Oncology, Department of Radiation Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Urol 169:1993-8. 2003
    ..There is no consensus on the treatment of these groups of patients. The role of radiotherapy, hormonal therapy or chemotherapy must be defined...
  43. ncbi request reprint Should routine screening for prostate-specific antigen be recommended?
    Siam Oottamasathien
    Division of Urology, Box c319, University of Colorado Health Sciences Center, 4200 E Ninth Ave, Denver, CO 80262, USA
    Arch Intern Med 163:661-2; discussion 666. 2003
  44. ncbi request reprint Early versus late hormonal therapy: debating the issues
    E David Crawford
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center, Denver, Colorado 80010, USA
    Urology 61:8-13. 2003
    ..Thus, accumulating evidence provides a rationale for continued investigation into the use of early hormonal therapy in selected patients...
  45. ncbi request reprint Three different strategies for real-time prostate capsule volume computation from 3-D end-fire transrectal ultrasound
    Albaha B Barqawi
    University of Colorado Health Science Center, Aurora, CO 80010, USA
    Conf Proc IEEE Eng Med Biol Soc 2007:816-8. 2007
    ..The mean volumes using the least square, level set and DDC techniques were 15.84 cc, 15.55 cc and 16.33 cc, respectively. We validated the methods by calculating the volume with GT and we got an average volume of 15...
  46. ncbi request reprint Prostate cancer. Introduction
    E David Crawford
    Division of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 62:1-2. 2003
  47. ncbi request reprint Emerging role of HIFU as a noninvasive ablative method to treat localized prostate cancer
    Al B Barqawi
    Section of Urologic Oncology, University of Colorado Health Sciences Center, Aurura, CO 80010, USA
    Oncology (Williston Park) 22:123-9; discussion 129, 133, 137 passim. 2008
    ..This review summarizes current knowledge about the basic principles of HIFU and its reported efficacy and morbidity in clinical series published since 2000...
  48. ncbi request reprint Genitourinary malignancies
    Shandra S Wilson
    Department of Urologic Oncology, Anschuz Cancer, Aurora, CO 80010, USA
    Cancer Chemother Biol Response Modif 22:485-513. 2005
  49. doi request reprint Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Urology 75:502-9. 2010
    ..Particular emphasis is placed on the design of the second large-scale trial of a 5alpha-reductase inhibitor, the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial...
  50. ncbi request reprint Metastatic cancer in solid tumors and clinical outcome: skeletal-related events
    Kyle O Rove
    University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA
    Oncology (Williston Park) 23:21-7. 2009
    ....
  51. ncbi request reprint A 72-year-old man with prostate cancer
    E David Crawford
    University of Colorado Health Sciences Center, Denver, USA
    Oncology (Williston Park) 16:1014-6, 1119-21. 2002
  52. ncbi request reprint My total prostate-specific antigen (PSA) level is 0.2 nanograms per milliliter, which I'm told is normal. But my free-to-total PSA ratio is 8 percent, which I've read indicates a high risk of prostate cancer. What do these seemingly contradictory PSA resu
    E David Crawford
    University of Colorado, Health Sciences Center, Aurora, Colorado, USA
    Health News 9:12. 2003
  53. ncbi request reprint Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptor
    Lin Qi
    Department of Medicine, Division of Medical Oncology, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Cancer Res 64:2090-5. 2004
    ..It may also be useful as a therapeutic agent to eliminate pituitary gonadotrophs, eliminating the need for chronic GnRH analogue administration to treat hormone-sensitive diseases...
  54. ncbi request reprint SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study
    Catherine E Klein
    University of Colorado, Denver, Colorado, USA
    Prostate 52:264-8. 2002
    ..Topotecan is a new topoisomerase-1 inhibitor whose early investigation suggested possible activity in hormone-refractory prostate cancer...
  55. ncbi request reprint Is a screening interval of every 4 years for prostate cancer acceptable?
    E David Crawford
    J Natl Cancer Inst 99:1279-80. 2007
  56. ncbi request reprint Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial
    Paul F Pinsky
    Division of Cancer Prevention, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA
    BJU Int 99:775-9. 2007
    ..To determine patterns of repeat prostate biopsy in a cohort of men undergoing prostate cancer screening who have a negative initial biopsy...
  57. ncbi request reprint Screening for prostate cancer in 2006: PSA in the 21st century
    Paul D Maroni
    Division of Urology, Department of Surgery, University of Colorado Health Sciences Center, USA
    N C Med J 67:136-9. 2006
  58. ncbi request reprint Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial
    Gerald L Andriole
    Division of Urologic Surgery, Washington University School of Medicine, St Louis, MO 63110, USA
    J Natl Cancer Inst 97:433-8. 2005
    ..We describe the population enrolled in the PLCO trial, their baseline PSA and DRE screening results, and diagnostic follow-up results during the first year of follow-up...
  59. ncbi request reprint Metastatic prostate cancer-does treatment of the primary tumor matter?
    Gregory Swanson
    Department of Radiation Oncology, University of Texas Health Science Center at San Antonio and Cancer Therapy and Research Center, San Antonio, Texas, 78229 3900, USA
    J Urol 176:1292-8. 2006
    ..We reviewed the effect of treating the principal disease bulk on overall treatment outcome in patients with advanced and metastatic cancer. Specifically we evaluated the role of surgical tumor cytoreduction...
  60. doi request reprint Multiple loci identified in a genome-wide association study of prostate cancer
    Gilles Thomas
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA
    Nat Genet 40:310-5. 2008
    ..Our findings point to multiple loci with moderate effects associated with susceptibility to prostate cancer that, taken together, in the future may predict high risk in select individuals...
  61. pmc Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)
    A Oliver Sartor
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 112:2393-400. 2008
    ..This study was designed to examine antiandrogen withdrawal effects within the context of a large multi-institutional prospective trial...
  62. ncbi request reprint Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
    Daniel P Petrylak
    Columbia University, New York, NY 10032, USA
    J Natl Cancer Inst 98:516-21. 2006
    ..We evaluated PSA changes as potential surrogate markers for survival by using data from a clinical trial...
  63. ncbi request reprint Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer
    Dominique S Michaud
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 66:4525-30. 2006
    ..At least seven common polymorphisms in genes of inflammatory cytokines IL-1B, IL-6, IL-8, and IL-10 do not seem to play a role in the risk of prostate cancer...
  64. ncbi request reprint Re: Prostate cancer in men using testosterone supplementation. F. D. Gaylis, D. W. Lin, J. M. Ignatoff, C. L. Amling, R. F. Tutrone and D. J. Cosgrove
    Abraham Morgentaler
    J Urol 175:1572; author reply 1573-4. 2006
  65. ncbi request reprint A prospective study of lycopene and tomato product intake and risk of prostate cancer
    Victoria A Kirsh
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Bethesda, MD 20892, USA
    Cancer Epidemiol Biomarkers Prev 15:92-8. 2006
    ..Dietary lycopene and tomato products may reduce risk of prostate cancer; however, uncertainty remains about this possible association...
  66. ncbi request reprint Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111
    Maha Hussain
    University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    J Clin Oncol 23:8724-9. 2005
    ..The epothilones are a new class of tubulin-polymerizing agents with activity in taxane-sensitive and resistant tumor models. We evaluated ixabepilone (BMS-247550) in patients with metastatic hormone-refractory prostate cancer (HRPC)...
  67. ncbi request reprint A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer
    E David Crawford
    Section of Urologic Oncology, University of Colorado Health Sciences Center, Aurora, Colorado 80045, USA
    J Urol 175:533-6. 2006
    ..The safety, efficacy and pharmacokinetics of LA-2585, a new 6-month subcutaneous depot of leuprolide acetate (Atrix Laboratories, Fort Collins, Colorado) were investigated in patients with prostate cancer...
  68. ncbi request reprint Minimally invasive surgery in prostate cancer: current and future perspectives
    Bulent Akduman
    University of Colorado Health Sciences Center, Anschutz Cancer Pavillion, Aurora, Colorado 80010, USA
    Cancer J 11:355-61. 2005
    ..In this review we critically discuss the current knowledge and future perspectives of minimally invasive treatment in prostate cancer...
  69. ncbi request reprint Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy
    E David Crawford
    Radiation Oncology, Department of Pathology, University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO 80045, USA
    BJU Int 96:999-1004. 2005
    ..To identify the precise location of prostate cancer within the gland and thus possibly permit more aggressive therapy of the lesion, while potentially sparing the noncancerous gland from ablative therapy...
  70. ncbi request reprint Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer
    Ashutosh Tewari
    Josephine Ford Cancer Center and Vattikuti Urology Institute, Henry Ford Health, System, Detroit, MI, USA
    BJU Int 96:29-33. 2005
    ....
  71. ncbi request reprint Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning
    Tracy R Glass
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Urol 169:164-9. 2003
    ..Risk stratification is helpful for designing clinical trials and individual treatment, and it should be incorporated into future reports of outcomes of patients with metastatic disease...
  72. ncbi request reprint Predicting the outcome of prostate biopsy in a racially diverse population: a prospective study
    Christopher R Porter
    Department of Urology, State University of New York, Stony Brook, New York, USA
    Urology 60:831-5. 2002
    ..To develop a mathematical model to predict prostate biopsy outcome using readily available clinical variables...
  73. doi request reprint Endogenous sex hormones and the risk of prostate cancer: a prospective study
    Jocelyn M Weiss
    Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, MD, USA
    Int J Cancer 122:2345-50. 2008
    ..T:SHBG ratio was related to risk in this older population of men, but the significance of this ratio in steroidal biology is unclear. (c) 2008 Wiley-Liss, Inc...
  74. ncbi request reprint A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer
    Thomas W Flaig
    Department of Medicine, University of Colorado Health Sciences Center, Aurora, CO 80045 0511, USA
    Cancer 107:266-74. 2006
    ..Preclinical data from prostate cancer cell lines suggested a synergistic effect of these therapies...
  75. ncbi request reprint Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024
    Gregory P Swanson
    University of Texas Health Science Center, San Antonio, USA
    J Urol 176:548-53; discussion 553. 2006
    ..Studies have shown that adding androgen ablation improves the results but there is still much room for improvement. We performed a phase II multi-institutional study to explore the feasibility of concomitant chemoradiotherapy...
  76. ncbi request reprint Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)
    Maha Hussain
    University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 24:3984-90. 2006
    ..To establish whether absolute prostate-specific antigen (PSA) value after androgen deprivation (AD) is prognostic in metastatic (D2) prostate cancer (PCa)...
  77. ncbi request reprint Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, MC 7845, 7703 Floyd Curl Dr, San Antonio, TX 78229 3900, USA
    JAMA 296:2329-35. 2006
    ..However, the optimal management of these patients after radical prostatectomy is unknown...
  78. ncbi request reprint Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial
    Paul F Pinsky
    Division of Cancer Prevention, National Cancer Institute, Bethedsa, Maryland, USA
    Urology 68:352-6. 2006
    ..Here we examine the relationship between prostate volume and PSA level in a large, geographically diverse sample of men undergoing prostate cancer screening...
  79. ncbi request reprint Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter
    Ian M Thompson
    Division of Urology, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, Tex, USA
    N Engl J Med 350:2239-46. 2004
    ..We investigated the prevalence of prostate cancer among men in the Prostate Cancer Prevention Trial who had a PSA level of 4.0 ng per milliliter or less...
  80. ncbi request reprint Prostate-specific antigen velocity and prostate cancer gleason grade and stage
    Paul F Pinsky
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer 109:1689-95. 2007
    ..The authors evaluated the relation between PSAV, biopsy Gleason score, and pathologic stage in men who were enrolled in a prostate cancer screening trial...
  81. ncbi request reprint Bone metabolism and new targets for intervention
    Bulent Akduman
    Department of Urology, School of Medicine, Zonguldak Karaelmas University, Zonguldak, Turkey
    Curr Urol Rep 8:233-8. 2007
    ..In addition to traditional treatment approaches, targeted therapy is currently becoming more popular. Bone metabolism, metastatic processes of prostate cancer, and the targeting of treatment for advanced disease are discussed here...
  82. ncbi request reprint Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia
    James R Marshall
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Cancer Epidemiol Biomarkers Prev 15:1479-84. 2006
    ..Subject accrual is expected to be completed by the fall of 2006, with trial completion in 2009...
  83. ncbi request reprint Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794
    Gregory P Swanson
    Department of Radiation Oncology and Urology, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
    J Clin Oncol 25:2225-9. 2007
    ..In this analysis, we stratified patients as to their preradiation PSA levels and correlated it with outcomes such as PSA treatment failure, local recurrence, and distant failure, to serve as guidelines for future research...
  84. ncbi request reprint The association of time of day and serum testosterone concentration in a large screening population
    E David Crawford
    Surgery and Radiation Oncology, Section of Urologic Oncology, UCHSC, Aurora, CO, USA
    BJU Int 100:509-13. 2007
    ....
  85. ncbi request reprint Ten-year survival in patients with metastatic prostate cancer
    Catherine M Tangen
    The Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Clin Prostate Cancer 2:41-5. 2003
    ..Although statistically significant baseline characteristics were identified in this clinical trial, they did not accurately predict the survival interval to which a patient belonged...
  86. ncbi request reprint IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
    Jocelyn M Weiss
    Division of Cancer Epidemiology and Genetics, NCI NIH, Bethesda, MD, USA
    Int J Cancer 121:2267-73. 2007
    ..11-7.08). In summary, our large prospective study showed no overall association between the insulin-like growth factor axis and prostate cancer risk, however, IGFmr was related to risk for aggressive prostate cancer in obese men...
  87. ncbi request reprint Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
    J Urol 172:2213-7. 2004
    ....
  88. ncbi request reprint Biochemical recurrence and survival prediction models for the management of clinically localized prostate cancer
    Ashuthosh Tewari
    Institute for Clinical Research at the Veterans Affairs, Medical Center Vattikuti Urology Institute and Josephine Ford Cancer Center, Henry Ford Health System, Detroit, MI, USA
    Clin Prostate Cancer 2:220-7. 2004
    ....
  89. ncbi request reprint The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer
    Marileila Varella-Garcia
    University of Colorado Comprehensive Cancer Center, UCHSC, Denver CO, USA
    Urol Oncol 22:16-9. 2004
    ....
  90. ncbi request reprint Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916
    R Bruce Montgomery
    University of Washington and Southwest Oncology Group Statistical Center, Seattle, Washington, USA
    J Urol 178:1946-51; discussion 1951. 2007
    ..We evaluated the effect of body mass index on prostate specific antigen response, and progression-free and overall survival in men with androgen dependent or androgen independent metastatic prostate cancer...
  91. ncbi request reprint Model to predict prostate biopsy outcome in large screening population with independent validation in referral setting
    Christopher R Porter
    Section of Urology and Renal Transplantation, Virginia Mason Medical Center, Seattle, Washington 98111, USA
    Urology 65:937-41. 2005
    ..To develop a model capable of predicting prostate biopsy outcomes in a large screening population, with independent validation in the referral setting...